How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and gastric cancer?

Patients with deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) harbor high tumor mutational burden which tends to have favorable response rates to immune checkpoint inhibitors.

Answer from: Medical Oncologist at Community Practice

Neoadjuvant immunotherapy is a reasonable option for patients with locally advanced dMMR/MSI-H esophagogastric cancer. The recently published GERCOR NEONIPIGA study provides some preliminary data. Among the patients who underwent surgery following neoadjuvant immunotherapy, 59% of patients achieved ...

Comments

Medical Oncologist at Cancer Center Overlook Hospital
In addition, there is data to suggest that giving ...

Medical Oncologist at Onc San Antonio
Would you consider an adaptive treatment strategy ...

Please select the option that best describes you:

How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and gastric cancer?

Related Questions